Abbott Laboratories $38.38

down 0.00


16/4/2014 06:40 PM  |  NYSE : ABT  
Industries : Health Services / Medical Appliances & Equipment
Get Trend Analysis Icon Get ABT Trend Analysis - it has underperformed the S&P 500 by 13%

Partner Headlines

  1. Abbott Labs Q1 sales, EPS fall

    IBD
  2. Market Wrap For April 16: Markets Hold On To Gains An Positive Yellen Comments ...

    Benzinga
  3. Abbott Q1 Performance Slips, But EPS Tops Estimates

    IBD
  4. Stock Futures In Positive Mode; Yahoo Rockets On Alibaba Boost

    IBD
  5. UPDATE: Abbott Posts Upbeat Q1 Earnings

    Benzinga
  6. Earnings Scheduled For April 16, 2014

    Benzinga
  7. Stocks To Watch For April 16, 2014

    Benzinga
  8. Intuitive Surgical Made Sci-Fi Dreams A Reality

    IBD
  9. Abbott Completes Enrollment of Absorb Randomized Clinical Trials in the ...

    Benzinga
  10. Absolute and Relative Valuation Models Indicate the Same: Abbot Is a Buy

    GuruFocus
  11. We Are Confident About Baxter's Plan to Create Two Separate Health Care ...

    GuruFocus
  12. Baxter Splitting In Effort To 'Unlock Trapped Value'

    IBD
  13. TripAdvisor: Yelp of Travel Looks Too Pricey

    YCharts
  14. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  15. Lountzis Asset Management Comments on Abbott Laboratories

    GuruFocus
  16. Abbott Capturing Incremental Market Share

    GuruFocus
  17. Abbvie's Humira Continues to be a Powerful Catalyst for Growth

    GuruFocus
  18. Morgan Stanley Sees 2015 Numbers Going Higher for Abbott Laboratories

    Benzinga
  19. AbbVie’s Testosterone: Impact of Health Concerns

    YCharts
  20. Morgan Stanley Maintains on Abbott Laboratories

    Benzinga
  21. Abbott EPS meets, sales miss

    IBD
  22. Abbott Labs Q4 Sales Miss Estimates; Earnings In Line

    IBD
  23. Earnings Scheduled For January 22, 2014

    Benzinga
  24. Stocks To Watch For January 22, 2014

    Benzinga
  25. UPDATE: Morgan Stanley Upgrades Abbott Laboratories

    Benzinga
  26. Diamond Hill Capital Comments on Abbott Laboratories

    GuruFocus
  27. Morgan Stanley Upgrades Abbott Based on Reacceleration

    Benzinga
  28. Dividend Aristocrat Johnson & Johnson Offers Growth

    IBD
  29. Drugmakers End Louisiana Suit Over Inflated Prices

    YCharts
  30. Johnson & Johnson (JNJ) Dividend Stock Analysis

    GuruFocus
  31. AbbVie Hepatitis C Treatment Shines In Latest Trials

    IBD
  32. Investing in Generation Y and the Next Great Baby Boom

    GuruFocus
  33. New Statin Rules: Which Drugmakers Had Ties?

    YCharts
  34. Johnson & Jonhson Unit Could Fetch Over $4 Billion in Sale

    Benzinga
  35. AbbVie’s AndroGel Testosterone Hit By Heart Study

    YCharts
  36. Where J&J $2.2B Settlement Fits Among Biggest

    YCharts
  37. AbbVie beats on Humira sales

    IBD
  38. AbbVie Earnings Beat Estimates; Street Eyes HCV Drugs

    IBD
  39. Generic Drug Industry: Top Five Players

    YCharts
  40. Starbucks Comes Under Official Chinese Criticism For Prices

    Benzinga
  41. 13 Companies Creating Real Wealth with Higher Cash Dividends

    GuruFocus
  42. 4 Big Players With Recent Dividend Growth To Consider

    GuruFocus
  43. Barron's Recap: Return Of The Bulls

    Benzinga
  44. Detecting Malaria Using a Cell's Electric Vibe

    FoxBusiness
  45. Market Primer: Thursday, October 17: US Debt Deal Kicks The Can

    Benzinga
  46. Abbott Q3 profit beats views

    IBD
  47. Stocks Open Higher, Trade Mixed; Piper Jaffray, Abbott Labs Rise

    IBD
  48. UPDATE: Abbott Posts Upbeat Q3 Profit, Lifts Dividend

    Benzinga
  49. Earnings Scheduled For October 16, 2013

    Benzinga
  50. Stocks To Watch For October 16, 2013

    Benzinga
Trading Center